- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
SIGA Technologies Inc(SIGA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SIGA
11/13/2026: SIGA (1-star) is currently NOT-A-BUY. Pass it for now.
SIGA Technologies is a specialized biotechnology firm primarily focused on providing medical countermeasures for biodefense, most notably through its FDA-approved antiviral treatment, TPOXX. Its primary business strength lies in its long-standing, sole-source relationship with the U.S. government for smallpox stockpile requirements. The company’s growth story hinges on expanding TPOXX into international markets and addressing emerging orthopoxvirus threats globally. However, the company faces significant risks, including heavy reliance on a single product, cyclical government procurement cycles, and political funding volatility. This stock may suit investors comfortable with binary outcomes and government-contract-driven performance rather than those seeking consistent, consumer-driven commercial growth or regular dividends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The growth is driven by episodic government contract cycles rather than steady commercial scaling. |
| Momentum investor | Strong fit while signal remains positive | Stock price often responds aggressively to news regarding major government contracts or health emergency headlines. |
| Value investor | Mixed fit | Valuation is often tied to the perceived probability of future government contract awards rather than traditional earnings multiples. |
| Dividend investor | Weak fit | The company does not provide a predictable, recurring dividend stream. |
| Low-risk investor | Weak fit | High revenue concentration and dependence on political/regulatory outcomes create significant binary risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp movements based on government procurement announcements. |
| Valuation risk | Medium | Valuation is sensitive to contract renewal timelines and political funding cycles. |
| Competition risk (government contracting) | Medium | The sector relies on a limited number of government buyers, creating high dependency risk. |
| Business quality | Medium | While the product is essential, the single-product reliance limits long-term franchise quality. |
| Dividend income | Low / none | The company does not offer regular dividend income for conservative investors. |
| Execution risk | Medium | Successfully fulfilling complex government contracts requires precision and regulatory adherence. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.88M USD | Price to earnings Ratio 274 | 1Y Target Price 17.53 |
Price to earnings Ratio 274 | 1Y Target Price 17.53 | ||
Volume (30-day avg) 534.2K shares | Beta 1.04 | 52 Weeks Range 2.71 - 6.29 | Updated Date 11/14/2026 |
52 Weeks Range 2.71 - 6.29 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -19.3% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| U.S. Government Contracting | Procurement of TPOXX for the Strategic National Stockpile. | The vast majority of revenue comes from large, infrequent orders from the U.S. government. |
| International/Commercial Sales | TPOXX sales to international governments and health organizations. | This is a secondary growth area aimed at diversifying revenue away from the U.S. government. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 274 | Forward PE 2.54 | Enterprise Value 80.78M | Price to Sales(TTM) 3.76 |
Enterprise Value 80.78M | Price to Sales(TTM) 3.76 | ||
Enterprise Value to Revenue 1.54 | Enterprise Value to EBITDA 3.71 | Shares Outstanding 71.86M | Shares Floating 41.12M |
Shares Outstanding 71.86M | Shares Floating 41.12M | ||
Percent Insiders 42.8 | Percent Institutions 47.26 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

